BioSpace News Archive

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker–guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).

BioVaxys Technology Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a Patent (“Patent”) for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulate with DPX™.

Alafair Biosciences, Inc. today announced its flagship product, VersaWrap® , has received an Innovative Technology contract from Vizient, Inc.

The urine sediment examination is primarily used to detect and assess kidney and urinary system health. In the conventional practice, a urine sediment test covers six items: red blood cells, white blood cells, squamous cells, urinary casts, crystals, and bacteria, while urine bacterial culture and pathological diagnostics may require an additional week.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder.

Genmab A/S and ProfoundBio, Inc. announced that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction.

EnteroBiotix Limited announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of IBS.

The Franche-Comté Polyclinic, part of ELSAN, the leading private hospital group in France, and Moon Surgical, a French-American pioneer in collaborative robotics, announced that the Maestro System is now being used clinically in gynecological laparoscopic procedures.

Molecure S.A., a biotechnology company that discovers and develops drugs to the clinical stage and leverages its globally unique expertise in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function to treat a range of incurable diseases, has published its 2023 annual report.

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical